



# INTRODUCING

# iStent *inject*<sup>®</sup> *w*..

Featuring a wide flange at its base, the new precision-engineered iStent *inject*<sup>®</sup> *w* is designed to optimize stent visualization while maintaining a truly micro-scale footprint, streamline implantation, and deliver procedural predictability.





## Injector System




Single v-slot window

Shorter window with bridge optimizes visualization of both stents




Rounded trocar tip

Tri-beveled trocar tip for reduced tissue tethering




Splayed trocar secures stents and assists improved delivery mechanism




Collet contains stents completely within circular tube

New collet "tines" rest behind the first stent, designed to facilitate the delivery process



# iStent inject® W




## EVOLVING DESIGN. ADVANCING PREDICTABILITY.

Its advantages are easy to see.

A WIDE FLANGE at the base of iStent inject® W is designed to:

- Enhance visibility
- Facilitate seamless implantation
- Provide observable positioning confirmation
- Deliver procedural consistency and predictability



### Built on a proven platform.

Representing the next generation of Glaukos trabecular micro-bypass technology, iStent inject® W is built on a solid, dependable foundation of proven efficacy and safety in thousands of eyes worldwide.

- **Optimized Outflow:** Two multi-directional stents designed to restore natural outflow
- **Clinically Proven:** Significant IOP reduction across a wide range of clinical studies<sup>1,2</sup>
- **Procedural Elegance:** Predictability and precision to meet the needs of your practice
- **Proven Safety:** Safety profile similar to cataract surgery alone<sup>1</sup>

All with the exceptional customer support you've come to expect from Glaukos.

GLAUKOS CANADA INC.

95 Mural Street • 6th Floor • Richmond Hill, ON • L4B 3G2 • CAN  
tel. 844.GLAUKOS (844.452.8567) • fax 844.452.8329 • Glaukos.com

GLAUKOS®

**INDICATION FOR USE.** The iStent inject® W (Model G2-W) is intended to reduce intraocular pressure safely and effectively in patients diagnosed with primary open-angle glaucoma, pseudo-exfoliative glaucoma or pigmentary glaucoma. The iStent inject® W can deliver two (2) stents on a single pass, through a single incision. The implant is designed to stent open a passage through the trabecular meshwork to allow for an increase in the facility of outflow and a subsequent reduction in intraocular pressure. The device is safe and effective when implanted in combination with cataract surgery in those subjects who require intraocular pressure reduction and/or would benefit from glaucoma medication reduction. The device may also be implanted in patients who continue to have elevated intraocular pressure despite prior treatment with glaucoma medications and conventional glaucoma surgery. **CONTRAINDICATIONS.** In eyes with primary angle closure glaucoma, or secondary angle-closure glaucoma, including neovascular glaucomas, in patients with retrolubar tumor, thyroid eye disease, Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure. **WARNINGS.** This device has not been studied in patients with uveitic glaucoma. The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure. iStent inject® W is MR-Conditional meaning that the device is safe for use in a specified MRI environment under specified conditions, please see labeling for details. Physician training is required prior to use and consists of 3 parts: webinar, Didactic session with Glaukos surgical representative and observation of surgical cases by Glaukos representative until implantation proficiency is demonstrated. Do not re-use the stent(s) or inserter. **ADVERSE EVENTS.** Postoperative adverse events include but are not limited to: early postoperative corneal edema, posterior capsule opacification, stent obstruction, intraocular inflammation (non-preexisting), BCVA loss and IOP increase requiring management with oral or intravenous medications or surgical intervention. Please refer to Directions for Use for additional adverse event information. **CAUTION:** Please reference the Directions For Use labeling for a complete list of contraindications, warnings and adverse events.

**REFERENCES:** 1. Samuelson TW, Sarkisian SR, Lubeck DM, et al. Prospective, randomized, controlled pivotal trial of an ab interno implanted trabecular micro-bypass in primary open-angle glaucoma and cataract. *Ophthalmology*. Jun 2019;126(6):811-821. 2. Hengerer FH, Auffarth GU, Riffel C, Conrad-Hengerer I. Prospective, non-randomized, 36-month study of second-generation trabecular micro-bypass stents with phacoemulsification in eyes with various types of glaucoma. *Ophthalmol Ther*. 2018 Dec; 7(2): 405-415.

©2020 Glaukos Corporation. Glaukos and iStent inject® W are registered trademarks of Glaukos Corporation.

PM-CA-0039